Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for Systemic Sclerosis
NORWOOD, MA--(Marketwired - June 16, 2016) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases …